RX‐3117, an oral hypomethylating agent to treat advanced solid tumors: Interim results from an ongoing phase 2a study in advanced urothelial cancer (aUC).

Authors

null

Meghan Salgia

City of Hope, Duarte, CA

Meghan Salgia , Sumanta K. Pal , Vincent M. Chung , Scott T. Tagawa , Joel Picus , Hani M. Babiker , Sumati Gupta , Julie Poore , Christine Peterson , Ely Benaim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT02030067

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 501)

DOI

10.1200/JCO.2018.36.6_suppl.501

Abstract #

501

Poster Bd #

K8

Abstract Disclosures

Similar Posters

First Author: Jacob Adashek

First Author: Nicholas Salgia

First Author: Vincent M. Chung

First Author: Drew Warren Rasco